These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1067 related articles for article (PubMed ID: 17852451)

  • 1. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.
    Steimle C; Lehmann U; Temerinac S; Goerttler PS; Kreipe H; Meinhardt G; Heimpel H; Pahl HL
    Ann Hematol; 2007 Apr; 86(4):239-44. PubMed ID: 17256145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
    Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
    Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
    Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 V617F mutation and PRV-1 overexpression: relevance in the diagnosis of polycythaemia vera and essential thrombocythaemia.
    Melis S; Vellinga S; Zachée P; Sierens AC; De Schouwer PJ
    Acta Clin Belg; 2009; 64(5):429-33. PubMed ID: 19999391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the JAK2 V617F mutation on PRV-1 expression.
    Mnjoyan Z; Yoon D; Li J; Delhommeau F; Afshar-Kharghan V
    Haematologica; 2006 Mar; 91(3):411-2. PubMed ID: 16503546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic control of PRV-1 expression on neutrophils.
    Jelinek J; Li J; Mnjoyan Z; Issa JP; Prchal JT; Afshar-Kharghan V
    Exp Hematol; 2007 Nov; 35(11):1677-83. PubMed ID: 17976520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
    Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.